Alicalm (polymeric liquid formula) ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 96 | Crohn disease | 1 |
96. Crohn disease
Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00609752 (ClinicalTrials.gov) | February 2008 | 24/1/2008 | Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease | Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease | Crohn Disease | Drug: prednisolone;Dietary Supplement: Alicalm (polymeric liquid formula) | University Hospital Birmingham | SHS International;Children's Memorial Research Foundation;St George's University Hospital Research Foundation | Recruiting | 7 Years | 17 Years | Both | 80 | Phase 4 | United Kingdom |